Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa.

Next Previous
X
Search
Trial Profile

Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir (Primary)
  • Indications Herpes simplex virus type 2 infections; HIV infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Dec 2022 Results deriving Vaginal microbiome data (n = 688) in the CAPRISA 004 , to study association between vaginal microbial dysbiosis and HIV susceptibility, published in the Clinical Infectious Diseases
    • 27 Oct 2017 Results presented at the 16th European AIDS Conference.
    • 26 Jul 2017 Results (n=48) assessing antibody dependent cell-mediated phagocytic activity in the genital tract mucosae of HIV-infected women with prior tenofovir gel exposure using an in vitro neutrophil-based functional assay presented at the 9th International AIDS Society Conference on HIV Science

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top